Pharmaceutical Exports Amounted To US$426.3 Million, Indicating That Much of the Market Is Import Driven - The Pharmaceutical Market: Finland.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49789) has announced the addition of The Pharmaceutical Market: Finland to their offering.

This in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Topics Covered:

1. Executive Summary

2. Pharmaceutical Market

3. Key National Data Projections

4. Geography

5. Political Overview

6. Economic Overview

7. Population

8. Demographic Indicators

9. Mortality

10. Morbidity 

11. Organisation & Administration

12. Health Expenditure

13. Hospital Services

14. Ambulatory Care 

15. Medical Personnel

16. Regulatory Environment

17. Distribution Channels

18. Pharmaceutical Imports

19. Domestic Production & Exports

20. Directory

The principal regulatory body in Finland is the National Agency for Medicines (NAM), operating under the Ministry for Social Affairs and Health. All pharmaceutical products, available on the domestic market and exported, must receive authorisation from NAM. NAM regulations stipulate conditions on the basis of quality, safety and effectiveness.

The principal authority regarding application for reimbursable status is the Pharmaceutical Pricing Board, affiliated to the Ministry of Social Affairs and Health. Other matters concerning reimbursable status are dealt with by the Social Insurance Institution (SII).

The NAM is viewed as a respected agency in the Mutual Recognition Procedure and is the leading agency in the EU as a reference state in the role of marketing authorisations.

The level of reimbursements has increased over the course of the past few years. In 2004, reimbursements were equal to 1,014.6 million euros (US$1,260.0 million), an increase of 10.6% over 2003. Many reasons have been given for this but of primary importance is the basic structure of the reimbursement system.

The vast majority of imports are in the form of retail medicaments, accounting for 93.7% of the US$1.2 billion of pharmaceuticals imported from a wide range of countries in 2003. Pharmaceutical exports amounted to US$426.3 million, indicating that much of the market is import driven.

For more information visit http://www.researchandmarkets.com/reports/c49789

Source: Espicom Business Intelligence